SIGA

SIGA Technologies Inc. - 2009 Annual Report (10-K) Summary

Business Context and Reporting Period

This report covers the fiscal year ended December 31, 2009. SIGA Technologies, Inc. is a biodefense company focused on the research, development, and commercialization of products to prevent and treat serious infectious diseases, particularly biological warfare agents. The company's lead product candidate is ST-246, an orally administered antiviral for smallpox. Revenue is derived almost exclusively from U.S. government grants and contracts, primarily with the National Institutes of Health (NIH).

Key Financial Metrics (Year Ended Dec 31, 2009)

Note: The 2009 net loss includes a non-cash loss of approximately $5.7 million related to changes in the fair value of common stock warrants classified as liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 71% to $13.8 million, driven by a $4.2 million increase in revenue from large-scale manufacturing and packaging of ST-246 and a $1.5 million increase from the $55 million NIH contract.
• Expense Increases: R&D expenses rose 50% to $17.4 million due to increased manufacturing, packaging, and stability testing for ST-246. SG&A expenses increased 64% to $7.5 million, largely due to higher legal fees ($1.3 million increase) and stock-based compensation.
• Liquidity Improvement: Cash and cash equivalents increased significantly from $2.3 million to $14.5 million. This was funded by $18.6 million in net proceeds from a December 2009 common stock offering and $7.4 million from warrant and option exercises.
• Accounting Change: On January 1, 2009, the company adopted ASC 815-40, resulting in a $2.7 million cumulative effect adjustment to the opening accumulated deficit to reclassify certain warrants as liabilities.

Guidance, Outlook, and Risks

• Product Development: ST-246 has received Orphan Drug designation and Fast Track status. The company estimates costs to complete development for adult therapeutic use will be $20–$25 million over 18–36 months. A Phase II clinical trial was ongoing in 2009.
• Government Contracts: In June 2009, BARDA deemed SIGA's response to a Request for Proposal (RFP) for 1.7 million courses of smallpox antiviral technically acceptable. However, no award is guaranteed, and final terms are subject to negotiation.
• Legal Contingency: PharmAthene, Inc. is suing SIGA regarding ST-246 licensing obligations. PharmAthene claims damages up to $1 billion. SIGA believes the claims are flawed and has meritorious defenses; no trial date is set, and loss is not estimable.
• Compliance Issue: In 2009, SIGA discovered it had not complied with DHHS regulations requiring yearly audited statements. The company submitted the required audits in September 2009 and requested no enforcement action, though the outcome remains uncertain.
• Outlook: Management expects to incur operating losses for the foreseeable future. The company believes existing funds and government contracts are sufficient to support operations for at least the next 12 months but will require additional financing to achieve profitability.

Key Facts for Investor Verification

• Revenue Concentration: Verify the sustainability of revenue streams, as 100% of 2009 revenue came from NIH contracts and grants.
• BARDA RFP Status: Monitor the outcome of the BARDA Smallpox RFP negotiation, as a contract award is critical for near-term commercialization.
• PharmAthene Litigation: Track the status of the lawsuit filed by PharmAthene, which seeks damages up to $1 billion and could impact IP rights to ST-246.
• Warrant Liability Volatility: Note that the company's net loss is significantly impacted by mark-to-market adjustments on warrant liabilities, which are sensitive to stock price volatility.
• Cash Runway: Confirm the company's ability to raise additional capital if government funding or the BARDA contract does not materialize as expected.